7月6日，诺诚健华(09969.HK)盘中上涨6.65%，报14.1港元，成交额7214.94万港元。
消息面上，公司自研靶向CDH17的新型ADC创新药ICP-B208完成首例患者给药，标志着该药物正式进入临床阶段。诺诚健华近期研发管线持续推进，此前ICP-054完成首例受试者入组、奥布替尼治疗ITP的新药上市申请获CDE受理、坦昔妥单抗联合疗法全球III期研究在EHA年会重磅发布，多项临床里程碑事件密集落地，叠加一季度药品销售收入同比增长44.54%的商业化放量趋势，市场对公司研发与商业化双轮驱动逻辑的认可度持续提升。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.